The ®rst direct evidence of a molecular distinction between haemophilia A and von Willebrand disease (vWD) came from the recognition of the dierence in inheritance pattern, X-linked in the case of haemophilia and autosomal dominant or recessive for vWD. It is interesting to note that though von Willebrand did distinguish vWD from haemophilia, he incorrectly concluded that vWD is inherited in an X-linked dominant pattern [1] . It was not until the elegant, landmark experiments of Nilsson and coworkers in 1957 that haemophilia and vWD were de®nitively established as due to de®ciencies of distinct proteins [2] .
von Willebrand factor (vWF) plays a central role in the critical initial phases of haemostasis [3±6] . The early confusion about the relationship between factor VIII (FVIII) and vWF stemmed from the fact that these two proteins are associated in plasma as a tight complex, with a stoichiometry of & 50±100 : 1 (vWF monomer:FVIII monomer). The primary haemostatic functions of vWF are the formation of an adhesive link between the platelet and the vessel wall at sites of vascular injury and the localization of FVIII to these sites for subsequent participation in the coagulation cascade leading to ®brin clot deposition (Fig. 1) .
vWF is produced within the endothelial cell and the megakaryocyte precursor of blood platelets (reviewed in [7] ), giving rise to distinct pools of platelet, plasma, and subendothelial vWF. vWF is ®rst synthesized as a single chain 300 kDa precursor protein, which subsequently dimerizes and multimerizes to form high molecular weight multimers that are then secreted into plasma via both constitutive and regulated pathways. vWF in the regulated pathway is stored in specialized granules within the endothelial cell termed Weibel±Palade bodies and is secreted in response to a variety of stimuli, including treatment with DDAVP.
The complexity of vWD
The bewildering complexity of the vWD clinical spectrum, with more than 20 subtypes described, has been made considerably more clear by recent advances in molecular genetics [4] . The newly revised classi®cation for vWD [8] recognizes two broad categories associated with either quantitative (type 1 and type 3) or qualitative (type 2) de®ciency of vWF. The current classi®cation scheme and the known genetic defects responsible for these variants are summarized in Table 1 . In type 3, or severe vWD, very low or undetectable vWF levels are associated with severe and often life-threatening bleeding, as in the proband of the original family from the A Ê land Islands. Type 1 vWD is the most common variant with a mild to moderate quantitative decrease in vWF. The most common type 2 variants, type 2 A and 2 B, are associated with loss of the largest and most haemostatically active vWF multimers. Type 2 N vWD is due to speci®c defects within the FVIII binding domain of vWF. Finally, the type 2 M classi®cation is reserved for the remaining miscellaneous variants that do not ®t well into any of the other categories.
The vWF gene
The critical advance opening the door to a molecular analysis of vWD was the cloning of the vWF cDNA in 1985 by four independent groups [9±12]. The structure of the vWF protein deduced from the cDNA, and con®rmed by direct amino acid sequence analysis [13] , is shown schematically in Fig. 2 . This summarizes a considerable body of work from multiple laboratories localizing speci®c functional domains within vWF [6] . The structure of the large and complex vWF gene, as well as identi®cation of a highly conserved partial pseudogene, was reported in 1991 by Sadler and coworkers [14] . The vWF gene spans 178 kb on the short arm of chromosome 12 and is composed of 52 exons. The characterization of full-length vWF cDNA [9] identi®ed a large propeptide which was shown to be identical to a previously known vWF-associated protein termed VW antigen 2 [15] . As shown in Fig. 2 been localized to an N-terminal 272 amino acid segment and the primary binding domain for the platelet receptor glycoprotein 1b has been mapped to the A1 repeat. The primary collagen binding domain appears to lie within the A3 domain whereas the RGDS sequence recognized by integrins, such as the GpIIbIIIa platelet receptor, is near the C-terminal end of the protein. Figure 3 illustrates the general molecular mechanisms that should be considered when examining the molecular basis of any genetic disease, including vWD. Perhaps the most obvious way to inactivate a gene is by deletion of a portion or all of the gene sequence itself. In the common genetic disorder a-thalassaemia, gene deletions account for the vast majority of patients. Although gene deletions have been identi®ed in a small subset of type 3 vWD patients, this appears to be a relatively rare mechanism for vWD. As expected, vWD gene deletion is generally associated with a quantitative de®ciency of vWF, though a single inframe deletion removing all three A domains has been reported in a patient with a type 2 variant [16] . A gene can also be inactivated by a single nucleotide substitution or point mutation, or the insertion or deletion of a few nucleotides within the DNA sequence. Mutations of this type can result in the substitution of a single amino acid (a missense mutation), an abrupt disruption of the coding sequence of the gene by introduction of a new stop codon (nonsense mutation), or a change in the reading frame (frameshift mutation). Small mutations of this type can also block the proper expression of the mRNA, either by interfering with normal RNA processing or transcription of the gene. Many of these mutations will result in loss of vWF expression from the mutant allele due to decreased or absent mRNA, or expression of an unstable or non-functional protein. However, missense mutations can also yield a stable vWF protein with a qualitative abnormality. Indeed, missense mutations are the underlying molecular basis for most of the qualitative (type 2) vWD variants.
Molecular basis of vWD
Finally, it is important to keep in mind the possibility that mutations in other genes outside of the vWF locus itself may interfere with vWF function, leading to vWD. This latter possibility can be addressed by performing linkage analysis, as illustrated at the bottom of Fig. 3 . The latter approach uses polymorphism in or near the vWF gene to trace the inheritance of the various vWF alleles within a speci®c family. A strong correlation between a speci®c vWF allele and vWD provides a clear indication that the disease in that family is due to a mutation within the vWF gene, even without knowing the precise nature of the mutation itself. Alternatively, occurrence of the same vWD phenotype in individuals in the same family who have not inherited a common copy of the vWF gene would strongly suggest a contribution from another gene. Though the contributions of other genes outside of the vWF locus to vWD is a subject of intense interest for our own research laboratory and others, it is important to stress that all of the limited studies that have been performed to date in classic vWD pedigrees have been consistent with linkage to the vWF gene [17] . The ®rst genetic defect to be identi®ed in patients with vWD were large gene deletions associated with type 3 vWD [18] . The advent of the polymerase chain reaction, which made it possible to amplify and sequence small amounts of vWF mRNA from peripheral blood platelets, led to the identi®cation of the ®rst point mutations in the vWF gene in two type 2 A vWD pedigrees [19] . Since that time, a large number of mutations have been identi®ed, accounting for most of the common qualitative (type 2) variants of vWD and these ®ndings have had important implications for our understanding of vWF structure and function, as illustrated in Fig. 2 . The known mutations have been periodically reviewed and catalogued [4 20] ; and an updated database is maintained on the World Wide Web by an international consortium of scientists (http://mmg2.im.med.umich.edu/vWF).
Type 2 A vWD
As illustrated in Fig. 2 , the vast majority of type 2 A vWD mutations are con®ned to the A2 domain. One of these mutations, Arg834Trp, is particularly common, accounting for & 1/3 of type 2 A vWD patients. The characteristic type 2 A vWD phenotype, loss of large and intermediate size vWF multimers, can arise via two distinct mechanisms [21] , as illustrated in Fig. 4 . In group 1 type 2 A vWD, the responsible mutation results in an improperly folded protein that is retained in the endoplasmic reticulum (ER) by the cell quality control machinery. In a heterozygous patient who carries one Finally, unknown mutations within the gene can be traced by linkage analysis, following the inheritance of a polymorphic DNA variation within or near the gene in members of families with the disease. A strong correlation between the specific vWF allele and the disease suggest that a mutation somewhere in the gene is responsible for the disorder. Alternatively, absence of such a correlation in a sufficiently large family would indicate that the disease is due to a mutation in another gene located elsewhere within the genome.
normal and one mutant copy of the gene, the larger vWF multimers, would be more likely to contain one or more mutant subunit. As a result, the largest multimers are retained in the ER and only the smallest multimers, presumably containing only the normal subunits, are secreted from the cell, accounting for the characteristic plasma vWF multimer pattern. This mechanism also accounts for the dominant inheritance of type 2 A vWD. In group 2, an entirely dierent mechanism is responsible for the dominant loss of large vWF multimers. Group 2 type 2 A vWF is normally secreted from the cell. However, the mutant subunits have an increased susceptibility to cleavage by a speci®c metalloproteinase present in plasma. This protease cleaves normal vWF between Tyr842 and Met843 [22] . Alterations in this process appear to account for the unusually large vWF multimers present in the plasma of patients with TTP [23, 24] . Group 2 type 2 A vWF is cleaved more readily by this protease resulting in loss of the largest multimers, again most likely to contain multiple mutant subunits. The resulting plasma vWF multimer pattern also shows loss of the largest and intermediate size multimers characteristic of type 2 A vWD, but by this second mechanism.
Why some mutations result in group 1 and others in group 2 type 2 A vWD is unknown. We hypothesize that both mechanisms may result from disturbance of the same speci®c structural motif within the A2 domain. When this structure is severely disrupted, the misfolded protein is recognized and retained within the ER. More subtle alterations may escape the cell quality control machinery but then render the protein more susceptible to proteolysis. Consistent with this hypothesis, similar amino acid substitutions can cause either group 1 or group 2 type 2 A vWD. For example, substitution of Glu at Gly742 results in group 2 type 2 A vWD whereas substitution of Arg at the same position causes a group 1 phenotype.
Type 2 B vWD
The molecular mechanism responsible for type 2 B vWD is distinct from that of type 2 A, though the phenotype is again characterized by loss of large vWF multimers. In type 2 B vWD, the mutation, generally resulting in a single amino acid substitution, leads to increased anity of vWF for its platelet receptor, GPIb, often associated with spontaneous binding. The resulting vWF platelet complexes are cleared rapidly from plasma, usually resulting in mild thrombocytopenia as well as loss of the largest, most haemostatically active vWF multimers. As shown in Fig. 2 , the vast majority of type 2 B vWD mutations are con®ned to the A1 repeat, helping to de®ne the GPIb binding domain within vWF. Indeed, four speci®c mutations within a 35 amino acid segment of the A1 domain account for & 90% of type 2 B vWD [25, 26] . The insights gained from molecular studies have led to the reclassi®cation of type 1 MalmoÈ and type 1 New York as type 2 B variants. These two disorders have been shown to be due to the same mutation in the vWF A1 domain [27] . Though quite similar to other type 2 B mutations, the resulting alteration of vWF function is more subtle and the vWF plasma multimers may appear normal, hence the earlier misclassi®cation as a type 1 variant.
Type 2N
As summarized in Table 1 , the type 2 N variant is associated with decreased vWF anity for FVIII, resulting in disproportionately low FVIII levels in plasma [28] . This phenotype results from the dependence of FVIII on binding to vWF to ensure its stability in plasma. The mutations responsible for type 2 N vWD are generally con®ned to the N-terminal segment of vWF, helping to further de®ne this critical functional domain within the protein.
Our group was the ®rst to identify the Arg91 to Gln mutation, the most common cause of type 2 N vWD [29] . Indeed, our ®ndings in the initial patient are instructive for the issues that should be kept in mind when evaluating missense mutations potentially associated with vWD. This patient exhibited disproportionately reduced levels of FVIII, most likely in conjunction with type 1 vWD (though the mechanism for the latter defect has not yet been characterized in this patient). The disproportionately low FVIII levels led us to sequence the FVIII binding domain by PCR ampli®cation of patient DNA. This analysis identi®ed two mutations in this region, Arg91Gln on one chromosome and Arg89Gln on the other! The remarkable similarity between these two amino acid substitutions initially left us puzzled as to whether one, both, or neither was actually responsible for the decreased FVIII binding. However, functional analysis of recombinant protein carrying each of these mutations demonstrated that the Arg89Gln mutation had no eect on FVIII binding whereas binding was markedly decreased by the Arg91Gln mutation. Consistent with this observation, screening of a large number of normal individuals demonstrated that the Arg89Gln mutation is a common polymorphism in the general population whereas Arg91Gln was only observed in the patient and none of the control samples. This particular mutation is found in over 50% of type 2 N patients and may be particularly common in some populations [30] . This mutation, along with most of the other reported type 2 N mutations, does not result in complete disruption of FVIII binding and in homozygous patients is associated with residual levels of FVIII in the range of 5%. Thus, type 2 N vWD should be in the dierential diagnosis for patients with mild or moderate haemophilia A, but is generally not confused with severe haemophilia A. However, a recent report [31] identi®ed a Glu24Lys mutation in a patient with & 1% FVIII levels, raising the concern that this diagnosis should also be considered in more severely aected patients. Type 2 N vWD provides an instructive example of locus heterogeneity; that is identical disease phenotypes due to mutations in dierent genes. The distinction between classic haemophilia A and type 2 N vWD is evident from the dierent inheritance patterns (X-linked recessive vs. autosomal recessive), though these diseases may have very similar clinical presentations and laboratory values. Indeed, it is likely that some previous reports of apparent haemophilia A in females or with an unusual inheritance pattern, may have been due instead to type 2 N vWD. These disorders can now be distinguished by a vWF FVIII binding assay, which is available in specialized clinical laboratories, particularly in Europe. As for the type 2 A and 2 B variants discussed above, direct DNA mutation detection has the potential to be of great clinical value but is not yet routinely available.
Type 1 and Type 3 vWD
The quantitative variants of vWD, type 1 and type 3, are clinically the most important. Type 3 is the most severe form and accounts for the majority of patient that require frequent or intensive medical care. Type 1 vWD, though generally mild, is by far the most common, accounting for * 70% of all cases of vWD. The prevalence of type 3 vWD has been estimated at & 1 : 1 000 000 [32±34], though it may be higher in Scandinavia. A number of mutations have been identi®ed in type 3 vWD patients including rare gene deletions as discussed earlier. The most common mutation is a deletion of a single nucleotide in a run of 6 cytosines in exon 18, resulting in a frameshift. This mutation was ®rst reported by BlombaÈ ck and coworkers and has been identi®ed in a number of type 3 alleles in Scandinavia, including the original A Ê land Island pedigree [35±37] .
What is the relationship between type 1 vWD and type 3? The simplest explanation is that type 1 vWD represents the heterozygous or carrier state for type 3 vWD. A mutation that inactivate the vWF gene will result in markedly reduced or absent vWF levels in the homozygote, leading to type 3 vWD. In the heterozygote, the presence of one inactivated and one normal allele should lead to vWF levels that are approximately half normal, resulting in mild bleeding. Though this may be the case in some type 1 patients, there are several problems with this simple explanation. First, in type 3 vWD, the inheritance is frequently described as`recessive' with the obligate carrier parents having no bleeding symptoms and often entirely normal vWF levels. In addition, the prevalence of type 1 vWD from epidemiological studies (as high as 1± 3% [38 39] ); would be predicted to lead to a much higher frequency of severe type 1 vWD than is observed.
The frequent lack of the manifestations of type 1 vWD among type 3 carriers may be explained by incomplete penetrance. Penetrance is the portion of individuals who carry the causative genetic mutation that exhibit the typical signs and symptoms of the disease. From evaluation of large pedigrees with type 1 vWD [40] , the penetrance of the disease is estimate at & 60% of obligate mutation carriers. It is likely that the penetrance of type 1 vWD is signi®cantly lower in unselected populations. Taking this penetrance ®gure into account, the true frequency of vWF gene mutation carriers could be considerably higher than the 1±3% estimated prevalence ®gures cited above, and even more incompatible with the observed frequency of type 3 vWD. These inconsistencies may be explained in part by over-diagnosis of type 1 vWD when based primarily on laboratory values, with somè patients' perhaps simply representing the edge of the normal distribution. Though it is also possible that some cases of type 1 vWD may be due to mutations at another genetic locus, as noted above, the limited linkage studies that have been published to date are all consistent with linkage to the vWF gene [17] .
It is also possible that speci®c type 3 vWD alleles cause symptoms in carriers, whereas other are silent. Our group has noted an association of gene deletions and other genetic defects leading to loss of vWF mRNA with recessive inheritance in type 3 families. In contrast, such alleles that are null at the mRNA level may be less frequent in type 1 families [17, 41] . Perhaps mRNA null mutations can be compensated for by increased production of vWF from the normal allele. Alternatively, the presence of an mRNA from the vWD allele may indicate a corresponding mutant protein that interfere with the expression of vWF from the normal allele. Eikenbloom and coworkers [42] have demonstrated such a dominant negative eect from mutation of a cysteine residue in the D3 domain of vWD. However, expression studies of the common exon 18 frameshift mutation failed to identify a similar mechanism for this allele, even though it is associated with both type 3 and type 1 vWD in the original A Ê land pedigree [37] .
Other genetic factors as modi®ers of plasma vWF level
A number of genetic and environmental factors are likely to contribute to the wide variability in clinical severity among type 1 vWD patients. Environmental variables such as thyroid hormone, oestrogen level, and stress are all know to signi®cantly modify plasma vWF levels [17] . In addition, genetic studies suggest that & 60% of the variation in plasma vWF levels is determined by genetic factors [43] . ABO blood group accounts for about 30% of this genetic eect, with plasma vWF levels in type O individuals 25±35% lower than in non-O individuals [44] . Thus, it appears likely that there are a number of other genetic factors that could have a dramatic eect on plasma vWF levels that, when taken together with ABO and environmental eects, could account for the wide variation in clinical severity and incomplete penetrance of type 1 vWD. It is also possible that a subset of type 1 vWD patients may have a combination of genetic modi®er mutations without any defect at the vWF gene itself. This hypothesis has important implications for the diagnosis and treatment of vWD.
Our laboratory has recently employed the mouse as a model system in which to study genetic modifying eects on plasma vWF levels. We have been studying the RIIIS/J inbred mouse strain ®rst identi®ed by Sweeney and coworkers [45] as a model for type 1 vWD. When compared to the common inbred strain C57BL6/J, RIIIS/J mice have plasma vWF levels that are & 50% of normal, with a normal multimer distribution. We initially showed that this alteration was not related to a defect within the vWF gene [46] and subsequently went on to identify the responsible gene as a novel genetic locus on mouse chromosome 11 [47, 48] . We have recently succeeded in identifying the responsible modi®er gene, which we have termed Mvwf for modi®er of vWF, as a previously known genetic locus, Galgt2 [49] . GALGT2 is a glycosyltransferase enzyme which transfers GalNac residues to a speci®c location on growing carbohydrate structures of both N-and O-linked sugars. The novel molecular mechanism we identi®ed as responsible for the low vWF level in RIIIS/J may have important implication, not only for vWF, but also for genetic modi®cation for a number of other plasma proteins.
The mechanism responsible for the Mvwf phenotype is illustrated in Fig. 5 . Normally Galgt2 is expressed primarily in the gut epithelial cell. The mutation in RIIIS/J turns o expression of this gene in the gut and instead turns it on in the entire vascular endothelial cell bed, the site of plasma vWF synthesis. Thus, the mutation in this disorder does not alter the GALGT2 protein structure itself, but rather changes its expression pattern. Expression of GALGT2 at the site of vWF synthesis results in a unique sugar structure not normally present on vWF. The altered vWF is rapidly cleared from plasma, with a half life of & 10 min, compared to the normal & 4±8 h of wild-type vWF. This results in a marked decrease in plasma vWF levels, as much as 20-fold (to 5%) when compared to certain wild mouse strains [49] .
The Mvwf molecular mechanism identi®ed in the RIIIS/J mouse provides a potential explanation for a possible subset of type 1 vWD unrelated to the vWF gene itself. It is unlikely that this unique and unusual mutation mechanism has also occurred independent in humans as a cause of human type 1 vWD. However, the general paradigm of altered protein processing determined by variation at other genes could certainly apply to human vWD, as well as diseases due to alterations in other plasma proteins. Continued advances in understanding the complex determinants of plasma vWF level should dramatically improve our future ability to precisely diagnose and classify this common human bleeding disorder. 
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